BETHESDA, MD and OSLO, NORWAY and PARIS--(Marketwire - October 19, 2009) -
| Highlighted Links |
Bionor Company Site |
Dr. Redfield has 25 years of continued clinical and clinical research activity with a primary focus on antiviral therapeutics and vaccine development, particularly in the area of targeting host cell pathways for their therapeutic potential.
Dr. Redfield is a pioneer in HIV clinical research, studying the newest and most effective biological treatments for HIV infection. His past accomplishments include: developing a system for determining the stage of HIV infection using "viral load" as a reference point, a system that is now standard around the world; being the first to demonstrate heterosexual transmission of HIV-1; and developing serological HIV screening procedures for the Department of Defense.
"I am excited about the opportunity to serve on the Clinical Advisory Board for such an innovative Company and I look forward to working with some of the greatest minds in HIV research today," said Dr. Redfield.
He currently oversees the clinical treatment of more than 4,000 HIV positive patients in the Baltimore/D.C. area as well as a treatment and care program under the President's Emergency Plan for AIDS Relief in nine African countries and the Caribbean. This plan has provided antiretroviral treatment to more than 50,000 people with HIV who would otherwise have no access to such medication.
Dr. Redfield is a passionate supporter of pursuing all avenues to find a cure for HIV/AIDS. In addition to antiretroviral research, he believes carefully monitored clinical trials of therapeutic and preventive HIV vaccines must be pursued vigorously.
About Vacc-4x
Vacc-4x is an HIV-1 immunotherapeutic vaccine comprised of synthetic peptides corresponding to conserved domains on the major core HIV-1 p24 capsid protein. Safety and tolerability have been confirmed in HIV-1-infected subjects following intradermal immunization schedules without serious adverse events.
As a therapeutic vaccination, it evoked strong, dose-dependent immune responses in a Phase IIa clinical trial, as determined by CD4+ and CD8+ T-cell proliferative responses as well as the intradermal skin test delayed type hypersensitivity (DTH). The response was sustained for the observation period of four years after immunization. CD4+ counts were increased in all patients after immunization and increases were more pronounced in those patients that had lower baseline CD4+ counts.
About Bionor Immuno
Bionor Immuno is an innovative biotech company developing synthetic peptide
vaccines that stimulate cell-mediated immunity. Previous efforts made to
use T-cell stimulation for vaccines have been notoriously unsuccessful and
this is the reason they are not on the market today. Bionor Immuno
carefully designs synthetic (modified) peptides with improved efficacy and
safety profiles. Among the diseases targeted are chronic infections caused
by HIV, Hepatitis C (HCV), Human Papilloma Virus (HPV) and Influenza.
Bionor Immuno's platform technology is universally applicable and makes it
possible to extend the range of projects to include vaccines targeting
cancer.
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati:
